Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Jan 31, 2027 to Sep 26, 2026
    • Study completion moved earlier from Aug 31, 2028 to Apr 3, 2028
    • Eligibility criteria expanded, about 82 words
    • Secondary endpoints: details revised at 2 of 6 entries
  2. Enrollment reduced: 15 → 9 participants
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v12
  3. Re-verified, no change to tracked fieldsv11
  4. Primary completion date: Jul 31, 2027 to Jan 31, 2027
    • Study completion date: Jun 30, 2029 to Aug 31, 2028
    • Eligibility criteria expanded, about 729 words
    • Secondary endpoints: 8 to 6
    v10
  5. Re-verified, no change to tracked fieldsv9
Show 7 earlier versionsHide 7 earlier versions
  1. Eligibility criteria shortened, about 10 wordsv8
  2. Primary completion date: Jul 31, 2025 to Jul 31, 2027
    • Study completion date: Jun 30, 2027 to Jun 30, 2029
    v7
  3. Eligibility criteria expanded, about 14 wordsv6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 31, 2022 to Dec 22, 2022
    • Eligibility criteria shortened, about 8 words
    • Site details revised
    v5
  5. Start date: Sep 30, 2022 to Dec 31, 2022
    • Primary completion date: Apr 30, 2025 to Jul 31, 2025
    • Study completion date: Mar 31, 2027 to Jun 30, 2027
    v4
  6. Re-verified, no change to tracked fieldsv3
  7. Eligibility criteria expanded, about 48 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Trial Details
NCT Number NCT05412290
Lead Sponsor Washington University School of Medicine
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
Related terms Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov